BioNTX Summit Spotlights 2025 Healthcare Rising Stars
BioNTX has named its 2025 Rising Stars—eight early- and growth-stage companies spanning diagnostics, therapeutics, delivery platforms, and surgical technologies—to...
No videos found.
Silo Pharma’s Breakthrough PTSD Drug Gets Australian Patent
IP Australia has granted patent number 2020271839 to Columbia University for the prophylactic use of serotonin 4 (5-HT4) receptor...
TG Therapeutics Starts New $100 Million Share Repurchase
TG Therapeutics has completed its previously authorized $100 million share repurchase program—buying roughly 3.5 million shares at an average...
Eisai Submits New Leqembi Subcutaneous Dose for Alzheimer’s
Eisai has begun a rolling FDA submission for a supplemental BLA to add a weekly, at-home initiation regimen for...
Cormedix Completes Melinta Acquisition, Surging Guidance
CorMedix has closed its acquisition of Melinta Therapeutics for $300 million upfront, adding seven marketed assets and a hospital-focused...
Zenas Biopharma Inks Sizable $300M Obexelimab Agreement
Royalty Pharma will provide up to $300 million in non-dilutive funding to Zenas Biopharma in exchange for a 5.5%...
Charm Therapeutics Soars with $80M for Breakthrough AML Drug
Charm Therapeutics has closed an oversubscribed $80 million Series B co-led by NEA and SR One to advance an...
Remarkable alloflo uveo Hits Milestones Ahead of Launch
Iantrek has added two peer‑reviewed studies to the evidence base for its AlloFlo Uveo bio‑reinforced cyclodialysis procedure, bringing the...
O-Mass, Genentech in Promising New IBD Therapy Agreement
Genentech has signed an exclusive collaboration and license with OMass Therapeutics to develop and commercialize OMass’s preclinical oral small-molecule...
Charm Therapeutics Soars with $80M for AML Drug Development
Charm Therapeutics has closed an $80 million oversubscribed Series B, co-led by NEA and SR One, to advance its...